A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

NCT07211633 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Multiple Sclerosis

Interventions

BIOLOGICAL: Ublituximab
BIOLOGICAL: Ublituximab

Sponsor

TG Therapeutics, Inc.